Research projects under PRIP scheme

1. At a Glance

• PRIP = Promotion of Research & Innovation in Pharma-MedTech Sector — a Central Sector Scheme of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, aimed at shifting India's pharma sector from cost-based to innovation-based growth [S2][S3].
• Total outlay ₹5,000 crore over the scheme period; two components — A (CoEs at NIPERs) and B (financial assistance to industry/start-ups/MSMEs) [S2].
• Currency for Prelims 2026: 710 industry/start-up/MSME project proposals were received by 19 Nov 2025; ₹183.46 cr released by 31 Jan 2026 to seven CoEs [S1].

2. Why in the News

• PIB release (10 Feb 2026) by Department of Pharmaceuticals: status update on PRIP — seven CoEs operational, ₹183.46 cr released, 710 proposals received from industry/start-ups/MSMEs by closing date 19.11.2025 [S1].
• Earlier (Jan 2025) call for proposals worth ~₹11,000 crore under Component B opened [S2].

3. Background & Evolution

• 17 Aug 2023: Union Health & Chemicals Minister Dr Mansukh Mandaviya launched the National Policy on R&D and Innovation in Pharma-MedTech Sector alongside the PRIP Scheme [S2].
• Scheme period: FY 2023-24 to FY 2027-28 (5 years); outlay ₹5,000 cr [S2].
• Predecessors/parallel: Bulk Drug Parks scheme, PLI for Pharmaceuticals, PLI for Medical Devices — PRIP shifts focus from manufacturing capacity to R&D and innovation [S2].
• 19 Nov 2025: closing date for industry/start-up/MSME proposal window under Component B [S1].

4. Core Static Facts

• Nodal body: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [S1].
• Total outlay: ₹5,000 crore [S2].
• Component A: Strengthening research infrastructure via Centres of Excellence (CoEs) at 7 NIPERs [S2].
• NIPER locations (7): Mohali, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur, Hyderabad [S2].
• CoE specialisations: anti-viral & anti-bacterial drug discovery; medical devices; bulk drugs; flow chemistry & continuous manufacturing; novel drug delivery systems; phyto-pharmaceuticals; biological therapeutics [S2].
• Component B priority areas (3): (i) new medicines, (ii) complex generics & biosimilars, (iii) novel medical devices [S2].
• Financial assistance — Early Stage (MSMEs/start-ups): project cost up to ₹9 cr, assistance up to ₹5 cr (100% of first ₹1 cr, 50% beyond) [S2].
• Financial assistance — Later Stage: project cost up to ₹285 cr, assistance up to ₹100 cr [S2].
• Funds released to CoEs: ₹183.46 cr (by 31.1.2026) [S1].
• Proposals received: 710 (by 19.11.2025) [S1].

5. Multi-Dimensional Analysis

Economic - Targets a sector valued at USD 50 bn (FY 2023-24) — domestic USD 23.5 bn + exports USD 26.5 bn [S2-related search result]. - Industry call worth ~₹11,000 cr in pipeline projects signals leverage ratio >2× on government outlay [S2].

Scientific / Technological - Promotes industry-academia linkage through NIPER CoEs in identified frontier areas (biologics, medical devices, continuous manufacturing) [S2]. - Bridges India's traditional generics strength with complex generics, biosimilars, and novel devices — areas dominated by US/EU/China [S2].

Administrative - Multi-stage appraisal process for financial assistance approval under scheme guidelines [S1]. - Funding routed via Department of Pharmaceuticals; NIPERs as implementing nodes under Component A [S1][S2].

Strategic (Atmanirbhar Bharat) - Reduces import dependence on APIs/KSMs (~70% from China earlier) and on high-end medical devices [S2]. - Complements Bulk Drug Parks and PLI schemes to build full-stack pharma self-reliance [S2].

6. Recent Developments (12-18 months)

• 13 Mar 2025: Industry dialogue on PRIP held at Mumbai [S2].
• Jan 2025: Call for proposals worth ~₹11,000 cr opened for industry/start-up projects under Component B [S2].
• 19 Nov 2025: Closing date — 710 proposals received [S1].
• 31 Jan 2026: ₹183.46 cr cumulatively released to seven CoEs [S1].
• 10 Feb 2026: PIB status update by Minister of State, Department of Pharmaceuticals [S1].

7. Prelims Hooks

• PRIP scheme launched on 17 August 2023 alongside the National Policy on R&D and Innovation in Pharma-MedTech Sector [S2].
• Implementing ministry: Ministry of Chemicals & Fertilizers (Dept. of Pharmaceuticals) — NOT Ministry of Health [S1].
• Total outlay: ₹5,000 crore [S2].
• Number of CoEs under Component A: 7, one each at every NIPER [S1][S2].
• NIPER campuses (7): Mohali, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur, Hyderabad [S2].
• Component B priority areas: new medicines, complex generics & biosimilars, novel medical devices [S2].
• Max assistance for Later Stage projects: ₹100 crore on cost up to ₹285 cr [S2].
• Max assistance for Early Stage (MSME/start-up): ₹5 crore on cost up to ₹9 cr [S2].
• Funds released to CoEs by 31.1.2026: ₹183.46 crore [S1].
• Proposals received by 19.11.2025: 710 [S1].
• NIPER Mohali is the first/flagship NIPER (Institute of National Importance under NIPER Act, 1998).
• PRIP launched by Union Minister Dr Mansukh Mandaviya [S2].

8. Mains Relevance

• GS-III: Indian Economy — Growth, Development; Science & Tech — indigenisation; Government Schemes.
• GS-II: Government policies for development of pharma sector; health-related governance.
• Plausible stems: 1. "The PRIP scheme marks a shift from cost-based to innovation-based growth in India's pharma sector. Discuss its design and challenges." 2. "Examine how PRIP, Bulk Drug Parks and PLI schemes together address India's pharmaceutical self-reliance." 3. "Critically evaluate the role of NIPER-based Centres of Excellence in catalysing pharma-medtech R&D in India."

9. Related Topics to Study Next

• PLI Scheme for Pharmaceuticals & Medical Devices — sister scheme on manufacturing.
• Bulk Drug Parks Scheme — backward integration on APIs/KSMs.
• NIPER Act, 1998 — statutory base for the seven institutes.
• National Policy on R&D and Innovation in Pharma-MedTech (2023) — parent policy of PRIP.
• Anusandhan National Research Foundation (ANRF) Act, 2023 — broader R&D financing architecture.
• Jan Aushadhi (PMBJP) — affordability counterpart.
• CDSCO & New Drugs and Clinical Trials Rules 2019 — regulatory ecosystem.
• India's API import dependence on China — strategic rationale.

10. Common Errors / Trap Areas

• Wrong ministry: PRIP is under Chemicals & Fertilizers (Dept. of Pharmaceuticals), not Ministry of Health & Family Welfare or DST.
• Confusion with PLI: PRIP funds R&D/innovation; PLI funds production.
• Component mix-up: Component A = CoEs at NIPERs; Component B = industry/MSME/start-up funding — easy to flip.
• NIPER count: There are 7 NIPERs covered under PRIP CoEs; total notified NIPERs in India is also 7 — do not conflate with IISERs/IITs.
• Outlay confusion: PRIP outlay = ₹5,000 cr (often mis-stated as ₹11,000 cr — that was the size of call for proposals, not scheme outlay).

11. Sources

• [S1] Research projects under PRIP scheme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2225734 — (tier: 1)
• [S2] PRIP Scheme aims to transform Indian Pharma-MedTech Sector… — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2200936 — (tier: 1)
• [S3] Dr Mansukh Mandaviya launches National Policy on R&D and Innovation in Pharma-MedTech & PRIP — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1960812 — (tier: 1)
• [S4] Call for proposals under PRIP worth ~₹11,000 crore — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2173970 — (tier: 1)
• [S5] Industry dialogue on PRIP, Mumbai, 13 March 2025 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2111230 — (tier: 1)